Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians

Clinical and Experimental Nephrology

Volumn 15, Issue 3, 2011, Pages 321-330

  Yokoyama, Hitoshi ^a   Okuyama, Hiroshi ^a   Yamaya, Hideki ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Asian; ISN RPS2003 classification; Japanese; Lupus nephritis; Race

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS;

ASIAN; B LYMPHOCYTE; BLADDER CANCER; CHRONICITY; DISEASE ASSOCIATION; DRUG RESPONSE; GONADAL DISEASE; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFECTION; JAPANESE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PATHOGENESIS; PREVALENCE; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; REMISSION; REVIEW; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; JAPAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79959214098     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0434-0     Document Type: Review

References (48)

1. Berden JH. Lupus nephritis. Kidney Int. 1997;52:538-58. (Pubitemid 27359601)
2. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002;112(9):726-9. (Pubitemid 34655662)
3. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of world wide disease burden. Lupus. 2006;15:308-18. (Pubitemid 43828810)
4. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244-54. (Pubitemid 46070148)
5. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128-40.
6. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-30. (Pubitemid 38130646)
7. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007;71:491-5.
8. Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K. An epidemiologic analysis of end-stage lupus nephritis. Am J Kidney Dis. 1994;23(4):547-54. (Pubitemid 24109117)
9. Cervera R, Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AO, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". Autoimmun Rev. 2006;5(3):180-6.
10. Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial. 2009;13(6):457-504.
11. Yokoyama H, Wada T, Hara A, Yamahana J, Nakaya I, Kobayashi M, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int. 2004;66:2382-8.
12. Okuyama H, Kimura S, Atsumi H, Imura J, Fujimoto K, Chikazawa Y, et al. Relationship between initial diagnosis and long-term prognosis in lupus nephritis. Nippon Jinzo Gakkai Shi. 2009;51(1):44-50. Japanese.
13. Hiramatsu N, Kuroiwa T, Ikeuchi H, Maeshima A, Kaneko Y, Hiromura K, et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford). 2008;47:702-7. (Pubitemid 351619216)
14. Kojo S, Sada KE, Kobayashi M, Maruyama M, Maeshima Y, Sugiyama H, et al. Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. J Rheumatol. 2009;36:2218-23.
15. Yokoyama H, Okuyama H. New insight into nephrotic lupus nephritis. Nippon Jinzo Gakkai Shi. 2010;52(7):903-7. Japanese.
16. Mittal B, Hurwitz S, Rennke H, Singh AK. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis. 2004;44:1050-9.
17. Hill GS, Delahousse M, Nochy D, Bariéty J. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005;68:2288-97. (Pubitemid 43117806)
18. Behara VY, Whittier WL, Korbet SM, Schwartz MM, Martens M, Lewis EJ. Pathogenetic features of severe lupus nephritis. Nephrol Dial Transplant. 2010;25:153-9.
19. Yu F, Tan Y, Wu LH, Zhu SN, Liu G, Zhao MH. Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center. Lupus. 2009;18(12):1073-81.
20. Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009;76:307-17.
21. Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol. 2009;5:212-20.
22. Sun HO, Hu WX, Xie HL, Zhang HT, Chen HP, Zeng CH, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus. 2008;17(1):56-61. (Pubitemid 351487021)
23. Schwartz MM. The pathology of lupus nephritis. Semin Nephrol. 2007;27:22-34.
24. Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16:175-9. (Pubitemid 43073170)
25. Albaqumi M, Soos TJ, Barisoni L, Nelson PJ. Collapsing glomerulopathy. J Am Soc Nephrol. 2006;17(10):2854-63. (Pubitemid 44484675)
26. Miura N, Mizuno N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, et al. Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol. 2009;13(1):85-8.
27. Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-9. (Pubitemid 16132725)
28. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248-57. (Pubitemid 32799338)
29. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000;343:1156-62.
30. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-28. (Pubitemid 41697285)
31. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-12.
32. Bao H, Liu ZH, Xieb HL, Hu WX, Zhan HT, Li LS. Successful treatment of class V + IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001-10.
33. Matsuyama N, Morimoto S, Tokano Y, Amano H, Nozawa K, Isonuma H, et al. The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide. Intern Med. 2010;49(9):823-8.
34. Tanaka Y, Yoshikawa N, Hattori S, Sasaki S, Ando T, Ikeda M, et al. Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial. Pediatr Nephrol. 2010;25(5):877-82.
35. Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28(1):6-12.
36. Austin HA III, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901-11.
37. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-60.
38. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4:579-87.
39. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62:2458-66.
40. Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR Study. Arthritis Rheum. 2009;60(Suppl):S429. (abstract).
41. Bosch X. Rituximab in ANCA vasculitis and lupus: bittersweet results. Nat Rev Nephrol. 2010;6:137-8.
42. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-toseverely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222-33.
43. Kim YG, Kim HW, Cho YM, Oh JS, Nah S-S, Lee C-K, Yoo B. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment. Rheumatology (Oxford). 2008;47:311-4. (Pubitemid 351267197)
44. Furness PN, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis - a UK-wide study. Am J Surg Pathol. 2006;30:1030-5. (Pubitemid 44264954)
45. Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: advances and implications. Arch Pathol Lab Med. 2009;133:233-48.
46. Arahata H, Migita K, Izumoto H, Miyashita T, Munakata H, Nakamura H, et al. Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins. Clin Rheumatol. 1999;18:77-81. (Pubitemid 29104763)
47. Morimoto S, Watanabe T, Lee S, Amano H, Kanamaru Y, Ohsawa I, et al. Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus. Mod Rheumatol. 2010;20:291-4.
48. Suzuki K, Kobayashi S, Yamazaki K, Gondo M, Tomizawa K, Arimura Y, et al. Analysis of risk epitopes of anti-neutrophil antibody MPO-ANCA in vasculitis in Japanese population. Microbiol Immunol. 2007;51:1215-20.